DD

ANALYST NOTE: DD (DuPont de Nemours, Inc.) Date: 2026-06-13 Analyst: StoryStocks-Native Equity Analyst

1. Structural Readiness

Current State: Forming Volatility Context: The current ATR is 3.1%, categorized as "productive." This indicates sufficient volatility to support a move but remains within the historical "sweet spot" (4–6% is ideal, but 3.1% is acceptable for a forming structure). The ATR at breakout is currently unmeasured as the breakout has not occurred.

2. Thesis Layer

Primary Secular Theme: Energy Transition & Electrification (EV Supply Chain). Exposure Weighting: Tertiary / Low Confidence. While DuPont is a member of the EV Supply Chain theme, management explicitly quantified this exposure as approximately $300 million in sales (E7). While this segment is described as "incremental growth" and growing "well above" the 20% industry expectation for EVs, it represents a specific, albeit growing, slice of the total portfolio rather than the dominant driver. Additional Secular Tailwinds:

• Healthcare & Aging Population: Management identifies the aging population and healthcare access as a "key global mega trend" driving medical packaging and biopharma needs (E8, E22).
• Water Scarcity & Regulation: The Water & Protection segment addresses critical challenges including water scarcity and increasing regulatory requirements for high-purity water (E22).
• Industrial Resilience: Strength in aerospace and automotive markets (excluding EVs) continues to support the Industrial Technologies segment (E12).

3. The Business

DuPont de Nemours, Inc. operates as a global provider of advanced materials and innovative solutions, organized into three primary segments: Electronics & Industrial, Mobility & Materials, and Water & Protection (E25).

• Electronics & Industrial: Provides materials for semiconductor manufacturing (front-end and back-end), printed circuit board fabrication, and advanced packaging (E26, E27, E28).
• Mobility & Materials: Supplies engineering resins, silicone encapsulants, and advanced films for transportation and industrial applications (E30).
• Water & Protection: Delivers solutions for worker safety, water purification, and medical packaging (E31).

Financial Performance & Guidance (as of May 5, 2026): Management has raised full-year 2026 guidance following Q1 performance and pricing actions to offset Middle East conflict-related input costs (E1).

• Net Sales: Midpoint guidance raised to $7.185 billion, an $80 million increase over prior guidance (E2). This assumes ~4% organic growth, with ~1% attributed to pricing actions (E3).
• Earnings: Adjusted EPS guidance raised to a range of $2.35 to $2.40, a $0.10 increase (E4).
• Q2 Outlook: Estimated net sales of $1.8 billion, operating EBITDA of $430 million, and adjusted EPS of $0.59 (E5).
• Segment Performance: Healthcare & Water Technologies net sales grew 6% to $806 million in Q1 2026, driven by a 3% organic increase and 3% favorable currency impact (E13). Industrial Technologies saw organic growth led by aerospace and automotive, offset by declines in printing and packaging (E12).

Strategic Actions:

• Restructuring: A "2026 DuPont Restructuring Program" was committed to in February 2026, targeting $100–$150 million in pre-tax cost savings from Q1 2026 through 2028 (E9).
• Capital Allocation: On May 5, 2026, the company announced an accelerated share repurchase of $275 million under a $2 billion authorization (E14).
• Divestitures & Separations: The Aramids business divestiture to Arclin was expected to close around Q1 2026 (E18). The separation of the Electronics Business into "Qnity Electronics, Inc." was completed via distribution on November 1, 2025 (E19).

4. Archetype and Conviction

Archetype: Quality Compounder (with elements of a Margin Inflector). Fit Analysis: DuPont fits the "Quality Compounder" archetype due to its consistent ability to generate organic growth through pricing power and volume gains in high-barrier markets (healthcare, water, aerospace). The recent restructuring program and the completed separation of the Electronics business (Qnity) suggest a strategic pivot to a leaner, higher-margin portfolio, acting as a margin inflector.

• Thesis Strength: Moderate. The EV exposure is real but tertiary. The core strength lies in the defensive, high-growth nature of Healthcare and Water segments.
• Evidence Quality: High. The evidence base is robust, featuring specific guidance raises, segment-level sales data, and clear strategic milestones (divestitures, buybacks) all confirmed as of May 2026.
• Structural Quality: The setup is "forming," which implies the market is digesting the recent guidance raise and strategic shifts. The 3.1% ATR suggests the stock is not in a parabolic state but is building a base.
• Rerating Potential: The rerating potential is tied to the successful execution of the restructuring savings ($100–$150M) and the realization of the 4% organic growth target. The market has not yet fully priced in the breakout, as the stock remains below the $52.66 resistance.

5. Invalidations, Strengths, and Gaps

What Would Strengthen the Case:

• A daily close above $52.66 (Breakout Level), confirming the coil structure.
• Further upward revisions to Q2 or Full Year 2026 guidance, particularly if organic growth exceeds the 4% target.
• Confirmation that the restructuring savings are realized ahead of the 2028 timeline.

What Would Invalidate the Case:

• A significant miss on Q2 earnings or a downward revision to full-year guidance, contradicting the May 5th raise.

Gaps in Evidence:

• Post-Event Performance: There is no evidence provided regarding the stock's performance between the May 5th earnings call and the June 13th event date, other than the current price of $47.71. The specific catalysts that moved the price from the May 5th close to the current level are not detailed in the provided evidence block.
• Qnity Distribution Impact: While the separation is noted as completed, the specific financial impact of the spin-off on DuPont's standalone balance sheet and cash flow for the remainder of 2026 is not quantified in the provided text.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: Management raised full-year 2026 net sales guidance to $7.185B and EPS to $2.35-$2.40; Healthcare & Water segment grew 6% organically in Q1; Restructuring program targets $100-$150M in cost savings. Key risks: Price action remains below breakout level of $52.66; EV exposure is tertiary and low confidence; Potential for broader industrial demand weakness in aerospace/printing sectors; Execution risk on restructuring timeline. Sizing hint: Position size should be conservative given the "forming" state; wait for breakout confirmation for full allocation. Expected path: Management expects continued organic growth and cost savings to drive EPS; stock likely to consolidate near current levels until a decisive move above resistance or a retest of support. Expected horizon: 3 to 6 months for structural confirmation or invalidation. Failure mode to watch: A daily close below $46.09, which would invalidate the forming coil structure.